Clinical Trial

Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)

Study acronym: EVERY
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Study design is multicenter prospective registry study. Participants are consecutive (non-selected, a sequential registration) patients admitted from emergency rooms of participating hospitals who meet the eligibility criteria. The primary objectives are to estimate the prevalence of and risk factors for RS and other respiratory virus infection and their effect on hospital course in patients with any respiratory symptom who admit from emergency room using a multicenter prospective registry study. The primary target virus is RS virus and the secondary target viruses are respiratory virus and other microorganisms measured by FilmArray 2.1.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-13; most recent amendment 2025-07-16.
Status change: Recruiting → Active, Not Recruiting 2025-07-16
Status change: Not Yet Recruiting → Recruiting 2023-06-30
Trial Details
NCT Number NCT05913700
Lead Sponsor Institute for Clinical Effectiveness, Japan
Collaborators: GlaxoSmithKline
Conditions Respiratory Syncytial Virus (RSV), Respiratory Viral Infection, Acute Disease
Enrollment 3,067 participants
Start Date 2023-07-01
Primary Completion 2025-01-22 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-20